KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exact Sciences (EXAS) Research & Development (2016 - 2025)

Exact Sciences has reported Research & Development over the past 16 years, most recently at $191.5 million for Q4 2025.

  • Quarterly Research & Development rose 95.99% to $191.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $523.0 million through Dec 2025, up 21.29% year-over-year, with the annual reading at $523.0 million for FY2025, 21.29% up from the prior year.
  • Research & Development was $191.5 million for Q4 2025 at Exact Sciences, up from $117.3 million in the prior quarter.
  • Over five years, Research & Development peaked at $191.5 million in Q4 2025 and troughed at $75.4 million in Q3 2021.
  • The 5-year median for Research & Development is $105.7 million (2022), against an average of $108.0 million.
  • The largest YoY upside for Research & Development was 225.15% in 2021 against a maximum downside of 80.18% in 2021.
  • A 5-year view of Research & Development shows it stood at $88.5 million in 2021, then rose by 7.41% to $95.0 million in 2022, then increased by 21.19% to $115.2 million in 2023, then decreased by 15.17% to $97.7 million in 2024, then surged by 95.99% to $191.5 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Research & Development are $191.5 million (Q4 2025), $117.3 million (Q3 2025), and $108.9 million (Q2 2025).